METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a blood pressure pill boost cancer treatment? new trial combines three therapies for head and neck cancer
Disease control Recruiting nowThis early-phase trial tests whether adding a common blood pressure drug (losartan) to immunotherapy (pembrolizumab) and precise radiation (SBRT) is safe and effective for people with head and neck cancer that has returned or spread. About 24 adults whose cancer cannot be surgica…
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of California, Davis • Aim: Disease control
Last updated May 17, 2026 02:21 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new oral drug called STC-15, either alone or combined with toripalimab, in people with advanced solid tumors or certain sarcomas (leiomyosarcoma and liposarcoma). The goal is to see if the treatment is safe and can shrink or control tumors. About 107 adults wit…
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: STORM Therapeutics LTD • Aim: Disease control
Last updated May 17, 2026 02:18 UTC
-
New combo therapy targets tough cancers using biomarker clues
Disease control Recruiting nowThis study tests two drugs, cabozantinib and nivolumab, in 150 people with advanced melanoma or head and neck cancer that hasn't responded to prior immunotherapy. The goal is to see if the combination shrinks tumors and how quickly doctors can use tumor biomarkers to sort patient…
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:04 UTC
-
Triple therapy aims to shrink advanced head and neck tumors
Disease control Recruiting nowThis study tests a combination of three treatments—modified immune cells (PD-L1 t-haNK), an immune-boosting protein (NAI/Anktiva), and a targeted antibody (cetuximab)—in 25 adults with advanced head and neck cancer that has returned or spread. The goal is to see if this mix can s…
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Glenn J. Hanna • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
Radioactive seeds plus immunotherapy take on hard-to-treat head and neck cancer
Disease control Recruiting nowThis study tests a new approach for people with head and neck cancer that has come back or spread and cannot be removed by surgery. Tiny devices that give off a special type of radiation are placed directly into the tumor, and patients also receive an immunotherapy drug called pe…
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Alpha Tau Medical LTD. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New hope for Hard-to-Treat head and neck cancer: drug combo trial launches
Disease control Recruiting nowThis study tests whether adding cetuximab to the immunotherapy drug pembrolizumab helps people with advanced head and neck cancer live longer. The cancer has either come back or spread and no longer responds to platinum chemotherapy. About 158 adults will be randomly assigned to …
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New vaccine combo aims to fight recurrent head and neck cancer
Disease control Recruiting nowThis early-stage trial tests a personalized vaccine made from a patient's own tumor cells, alone or with the immunotherapy drug pembrolizumab, for head and neck cancer that has returned or spread. The goal is to find the safest dose and see if the vaccine helps the immune system …
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New drug duo aims to extend life in tough-to-treat head and neck cancer
Disease control Recruiting nowThis phase 3 study tests whether adding ficlatuzumab to standard cetuximab helps people with recurrent or metastatic HPV-negative head and neck cancer live longer or keep their cancer from growing. About 410 adults will receive either the combination or a placebo plus cetuximab. …
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: AVEO Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Tailor-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if this combination is safe and helps the immune system fight cancer more effectively. A…
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New drug duo aims to shrink head and neck tumors
Disease control Recruiting nowThis study tests whether adding ficerafusp alfa to standard immunotherapy (pembrolizumab) can shrink tumors or extend life in people with advanced head and neck cancer that has spread or come back. About 650 adults with PD-L1-positive cancer will receive either the combination or…
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Bicara Therapeutics • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
Cholesterol drug boosts immunotherapy in head and neck cancer trial
Disease control Recruiting nowThis study tests whether adding the cholesterol-lowering drug lovastatin to the immunotherapy pembrolizumab can shrink tumors in people with head and neck cancer that has returned or spread. About 28 adults whose cancer has a specific marker (PD-L1 CPS≥1) will receive both drugs.…
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New hope for head and neck cancer: drug works after immunotherapy fails
Disease control Recruiting nowThis study tests whether the drug cetuximab can shrink tumors in people with head and neck cancer that has spread or come back, after they have already tried immunotherapy. About 38 adults will receive cetuximab alone. The main goal is to see how many patients' tumors shrink or d…
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
New scan could spot hidden cancer spread in head and neck patients
Diagnosis Recruiting nowThis study tests a new imaging drug called 89Zr panitumumab to see if it can more accurately find cancer that has spread in people with head and neck cancer. Standard PET/CT scans often miss or wrongly identify these spots. About 60 participants will receive the new imaging agent…
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Eben Rosenthal • Aim: Diagnosis
Last updated May 17, 2026 02:17 UTC
-
New PET tracer could spare head and neck cancer patients unnecessary biopsies
Diagnosis Recruiting nowThis early-phase study tests a new radioactive tracer called [18F]NOTA-ABY030, which is designed to make head and neck squamous cell carcinoma show up more clearly on PET/CT scans. About 25 adults with suspicious or unclear findings on standard scans will receive the tracer and u…
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Diagnosis
Last updated May 17, 2026 02:08 UTC
-
Morning vs. afternoon: can timing boost cancer immunotherapy?
Symptom relief Recruiting nowThis study looks at whether getting immunotherapy in the morning or afternoon changes how well it fights advanced or metastatic solid tumors. Researchers believe the body's internal clock (circadian rhythm) might affect immune response. About 160 adults with certain cancers like …
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE4 • Sponsor: OHSU Knight Cancer Institute • Aim: Symptom relief
Last updated May 17, 2026 02:18 UTC
-
Cancer patients may soon get immunotherapy at home – no more long clinic trips!
Symptom relief Recruiting nowThis study looks at whether giving the cancer drug nivolumab as a shot at home is as good as getting it at the clinic. About 50 adults with various cancers will try both ways to see which they prefer and how it affects their quality of life. The goal is to reduce the time, cost, …
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated May 17, 2026 02:17 UTC
-
Remote hearing tests could save cancer Patients' hearing
Knowledge-focused Recruiting nowThis study looks at whether offering hearing tests close to home or remotely can help more head and neck cancer patients get their hearing checked during and after treatment. Many patients on cisplatin chemotherapy or radiation may lose hearing, but traveling to the clinic for te…
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Emory University • Aim: Knowledge-focused
Last updated May 11, 2026 20:38 UTC